Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.49 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.49 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.49 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.49 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.49 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15000860 | 0.94 | GNAI3 (0.51) | ITGB3ITGA2BGPR119FAAHGNAI3 | |
| Hydrochloric Acid SCHEMBL1532657 | 0.93 | GNAI3 (0.53) | ITGB3ITGA2BGPR119FAAHGNAI3 | |
| SCHEMBL15085741 | 0.91 | GPR119 (0.59) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL4038117 | 0.90 | HPGD (0.49) | GPR119FAAHGNAI3GNAO1GNAI1 | |
| SCHEMBL29201747 | 0.87 | TPSAB1 (0.49) | ITGB3ITGA2BGPR119FAAHTPSAB1 | |
| SCHEMBL27035708 | 0.87 | GPR119 (0.49) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL27124589 | 0.87 | HPGD (0.47) | GPR119FAAHHPGDKDM4EPKM | |
| SCHEMBL8993970 | 0.87 | HPGD (0.47) | GPR119FAAHGNAI3GNAO1GNAI1 | |
| SCHEMBL27137696 | 0.87 | GPR119 (0.52) | GPR119FAAHTPSAB1TPSD1TPSG1 | |
| Acetic Acid SCHEMBL31129570 | 0.86 | KDM4E (0.48) | ITGB3ITGA2BGPR119FAAHHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20240261418-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2024-08-08 | — | — | US | disclosed |
| CN-115232114-B | SOS1 degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2023-12-19 | — | — | CN | disclosed |
| WO-2022223034-A1 | SOS1 DEGRADATION AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海领泰生物医药科技有限公司 | 2022-10-27 | — | — | WO | disclosed |
| CN-115232114-A | SOS1 degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
| EP-2607362-B1 | Piperidine and piperazine carboxylates as FAAH inhibitors | ASTELLAS PHARMA INC (JP) | 2014-12-31 | — | — | EP | disclosed |
| EP-1849773-B1 | Piperazine derivatives for the treatment of urinary incontinence and pain | ASTELLAS PHARMA INC (JP) | 2013-10-16 | — | — | EP | disclosed |
| EP-2607362-A1 | Piperidine and piperazine carboxylates as FAAH inhibitors | Astellas Pharma Inc. (JP) | 2013-06-26 | — | — | EP | disclosed |
| US-7919494-B2 | Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound | ASTELLAS PHARMA, INC. (JP) | 2011-04-05 | — | — | US | disclosed |
| US-7919495-B2 | Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound | ASTELLAS PHARMA, INC. (JP) | 2011-04-05 | — | — | US | disclosed |
| US-7915261-B2 | Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound | ASTELLAS PHARMA, INC. (JP) | 2011-03-29 | — | — | US | disclosed |
| US-20100009971-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20100009972-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20080306046-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Derivative | FMC CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| EP-1849773-A1 | PYRIDYL NON-AROMATIC NITROGENATED HETEROCYCLIC-1-CARBOXYLATE ESTER DERIVATIVE | Astellas Pharma Inc. (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240261418-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SOS1, RAC1, RSU1 | ITGB3 3824/4885ITGA2B 3848/4885GPR119 3494/4885 |
| US-20080306046-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Derivative | FAAH, FAAH2, APEH | ITGB3 3765/4885ITGA2B 3807/4885GPR119 501/4885 |
| US-20100009972-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound | FAAH, FAAH2, CNR2 | ITGB3 3443/4885ITGA2B 3613/4885GPR119 2513/4885 |
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | KRAS, NRAS, HRAS | ITGB3 2086/4885ITGA2B 3198/4885GPR119 2528/4885 |
| US-20100009971-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound | FAAH, FAAH2, CNR1 | ITGB3 3443/4885ITGA2B 3635/4885GPR119 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.